NEUP: bionomics.com.au Market Value to Book Value Ratio
The price chart for Neuphoria Therapeutics Inc. (NEUP) on GURU.Markets helps assess the outlook for expanding its small molecule portfolio to combat PTSD and anxiety, where the metric stands at 0.67. Development relies on the seamless operation of laboratories and partner manufacturing plants. Business success is based on the synergy between chemists and physicians who maintain full creative freedom in developing innovative medicines.
Neuphoria Therapeutics Inc. (NEUP) - metric breakdowns and financial figures
- market value and analyst target forecast:
- market capitalization information:
- book capitalization data:
- debt and solvency information:
Debt to Equity Neuphoria Therapeutics Inc.|NEUP - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity bionomics.com.au|NEUP - Company Cumulative Debt|Debt to Book Capitalization Ratio Neuphoria|NEUP - Company Long-Term Indebtedness|Company Short-Term Debts Neuphoria Therapeutics|Quick Liquidity Indicator bionomics.com.au
- earnings and valuation multiples indicators:
Comprehensive company analysis:Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. (NEUP) is actively advancing clinical trials for PTSD drugs in collaboration with global pharma behemoths. These intangible successes are capitalized through the price-to-book ratio. This metric measures the premium or discount of the share price relative to the business's book value. High values indicate market expectations for future breakthroughs in anxiety therapy. Analyzing the price-to-book value multiple helps determine the extent of the asset's overvaluation.
Key competitors
Biogen Inc. (BIIB) - Market Value to Book Value Ratio|Market Capitalization to Net Assets NBIX (neurocrine.com)|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|XENE - Market-to-Book Ratio|Viking Therapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio supernus.com SUPN|CPRX - Market Value to Book Value Ratio|Market Value to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Market Value to Book Value Ratio|Market-to-Book Ratio Biohaven Corp (BHVN)|Market Value to Book Value Ratio Amylyx Pharmaceuticals|Capitalization to Book Value Ratio TRVI (trevitherapeutics.com)|Market Capitalization to Book Value Ratio PRAX|AVXL - Market-to-Book Ratio|CeriBell Corp - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Prothena PRTA|ALEC - Market Value to Book Value Ratio|Market Capitalization to Net Assets ANNX|OMER: Market Capitalization to Book Value Ratio|Neurogene Inc - Market Value to Book Value|Market Value to Book Value Ratio AC Immune Corp|Market-to-Book Ratio Voyager Corp VYGR|Market Value to Book Value Ratio Neumora Therapeutics (NMRA)|SCLX (scilexholding.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio TVGN (Tevogen Bio)|Market Capitalization to Book Value Alpha Cognition Inc (ACOG)|Cognition Therapeutics, Inc. - Market Capitalization to Book Value Ratio|IKT - Market Capitalization to Book Value Ratio|SAVA (Cassava Sciences, Inc.) - Market Cap to Net Assets Ratio|Assertio - Market Value to Book Value|Market Cap to Net Assets Ratio COYA|VTGN (VistaGen Therapeutics Inc) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio OVID|ABOS (Acumen Pharmaceuticals, Inc) - Market Value to Book Value|Market Capitalization to Book Value Ratio CRVO (CervoMed Inc.)|Alterity Therapeutics Ltd. (ATHE) - Market-to-Book Ratio|CLNN - Market Value to Book Value Ratio|Market Value to Book Value PEPG (PepGen Inc.)|JUNS: Market Capitalization to Book Value Ratio|Relmada Corp (RLMD) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Annovis Bio, Inc.|Grace Tx - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio AIFF|KLTO - Market-to-Book Ratio|NeuroSense Therapeutics Ltd. - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Reviva Pharmaceuticals, Inc. RVPH|MTVA: Market Cap to Net Assets Ratio|neuraxis.com - Market Cap to Book Value Multiple|HSDT: Market Capitalization to Book Value Ratio|PASG - Market Capitalization to Book Value|NERV (Minerva Neurosciences Corp) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Athira Pharma Corp (ATHA)|Market Value to Book Value Ratio Addex Therapeutics (ADXN)|Market Capitalization to Book Value alzamend.com|Cyclerion Therapeutics, Inc. - Market Cap to Net Assets Ratio|Market Value to Book Value PTIX|Pasithea - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Cortigent, Inc. CRGT|Avenue Therapeutics (ATXI) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio BCLI|CARA (Cara Therapeutics) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Chromocell Therapeutics Corp (CHRO)|Market Cap to Net Assets Ratio ELYM (Eliem Therapeutics)|Market Capitalization to Book Value intracellulartherapies.com|Market Value to Book Value Ratio Longboard Pharmaceuticals LBPH|MRNS: Capitalization to Book Value Ratio|NKGen Biotech - Market Capitalization to Book Value Ratio|Market-to-Book Ratio NeuroBo Pharmaceuticals Inc|SAGE (Sage Therapeutics, Inc) - Market Cap to Net Assets Ratio|Synaptogenix, Inc (SNPX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Trevena, Inc.|Vigil Neuro - Market Capitalization to Net Assets|Market Value to Book Value Ratio Anew Medical, Inc. (WENA)|Cerevel Therapeutics Inc - Capitalization to Book Value Ratio